The FDA Has Approved Remdesivir for the Treatment of COVID-19

En español

The Food and Drug Administration has approved the antiviral drug remdesivir, sold under the brand name Veklury, as a treatment for COVID-19, the disease caused by the novel coronavirus. After reviewing a number of clinical trials the FDA has found that remdesivir is safe and effective as a treatment in adults and children 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.  The drug must be given in a health-care setting such as a hospital or similar setting capable of inpatient care. 

It is important for people with lupus to know that the FDA also notes there is a risk that remdesiver will not work as well if it is given along with chloroquine phosphate or hydroxychloroquine sulfate. Patients should always tell their healthcare provider about the use of any other prescription or nonprescription medication or herbal products, including chloroquine phosphate or hydroxychloroquine sulfate when being given remdesiver. 

Remdesivir is the first treatment for COVID-19 to be approved by the FDA. Other drugs are still being tested and offered on a trial basis. Keep in mind that remdesivir is a treatment, not a cure. People with lupus should still take steps to protect themselves from getting COVID-19 by wearing masks, engaging in frequent handwashing, and social distancing whenever possible.